MannKind Corporation MNKD

MannKind reports early demand for ReadyFlow as its pediatric Afrezza launch gains momentum. Early ReadyFlow demand and pediatric Afrezza launch momentum signal potential revenue growth and improved market positioning for MannKind.

MannKind Corporation advances inhaled weight loss treatments while reporting widening losses. Strategic push into inhaled weight loss marks major move likely to shift company trajectory and investor views despite rising losses.

MannKind Corporation enters weight loss market through Rose Pharma deal, prompting investor focus on expansion implications. Deal opens new weight loss market for MannKind, likely shifting company trajectory and investor sentiment.

MannKind and Rose Pharma Inc enter licensing and collaboration agreement to develop inhaled rapid-acting short-duration GLP-1 for weight management. Deal launches MannKind into high-growth weight management space via novel inhaled GLP-1 candidate with major strategic potential.

MannKind (MNKD) stock may be undervalued by 48% based on Afrezza performance and pipeline outlook. Afrezza results and pipeline updates can moderately shift investor views on MNKD valuation.

MannKind Corporation posted record revenue for Q2 2026 and highlighted several major catalysts for future growth. Record revenue and major catalysts point to substantial positive effects on company trajectory.

Wedbush states that MannKind's diversified portfolio is expected to result in higher revenue during the second half of the year. Analyst forecast of revenue growth from portfolio diversification indicates moderate influence on future performance and sentiment.

MannKind Corporation reported second quarter 2026 financial results and provided a business update. Quarterly earnings releases and business updates directly shape investor views on financial health and future trajectory.

MannKind Q2 earnings call covered financial results, Afrezza sales progress, pipeline updates and strategic outlook. Quarterly earnings call supplies performance data and guidance that can shift near-term sentiment and valuation but rarely alters long-term trajectory.

MannKind Corporation reported a Q2 net loss while surpassing revenue forecasts. Standard quarterly earnings with a loss offset by revenue beat typically trigger moderate short-term stock moves without reshaping long-term trajectory.

MannKind reports positive Phase 1b INFLO-1 results confirming safety and tolerability of Nintedanib DPI along with clinical validation of its DPI technology in IPF patients. Positive Phase 1b data on Nintedanib DPI and DPI platform validation advance core IPF program and strengthen MannKind's development prospects.

MannKind’s inhaled IPF drug cleared Phase 1b safety hurdle with Phase 2 now underway. Phase 1b clearance and Phase 2 initiation mark pipeline progress with limited near-term financial effect.

FDA approves MannKind's at-home treatment option for heart failure or kidney disease. FDA approval grants MannKind access to major new therapeutic markets with direct revenue potential.

MannKind Corporation secures FDA approval for at-home Furoscix autoinjector, enabling expanded product access and potential new revenue from self-administered treatment. FDA approval for new autoinjector product enables commercialization and revenue growth for MannKind.

Furoscix approval triggers debate on MannKind (MNKD) shares as either a buying opportunity or fully priced in by investors. Furoscix approval creates moderate short-term market sentiment shift for MNKD without major trajectory change.

MannKind stock rose 8% after Furoscix ReadyFlow received regulatory approval and the company secured a 50 million dollar funding boost. Product approval plus 50 million dollars in funding materially improves MannKind's commercial prospects and balance sheet.

MannKind wins FDA approval for Furoscix ReadyFlow and secures $50M PIPE financing. FDA approval enables new product commercialization while $50M PIPE bolsters capital for operations and growth.

MannKind's Furoscix Auto-Injector approval and launch may deliver strong upside to 2026 revenue expectations, according to Wedbush. Furoscix approval and launch expected to substantially boost MannKind 2026 revenues.

MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing. FDA approval of Furoscix ReadyFlow plus $50 million financing marks major regulatory and financial advances for MannKind.

MannKind obtains FDA approval for Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease. FDA approval of novel Furoscix ReadyFlow autoinjector opens major new revenue streams in heart failure and kidney disease markets for MannKind.

MNKD stock rises in premarket trading ahead of FDA verdict, fueled by retail investor optimism. Pending FDA verdict on core product can significantly shift company trajectory and investor sentiment.

MannKind Corporation raises $50 million via private placement. $50 million private placement supplies capital that supports operations without shifting competitive position.

MannKind director sold shares signaling potential risk to $32.7 million in quarterly royalties revenue. Potential royalty revenue risk points to moderate effects on MannKind financial performance.

MannKind Corporation sold Tyvaso royalties for $32.7 million, indicating a strategic move to monetize assets. Royalties sale delivers immediate cash to MannKind while cutting recurring future revenue.

MannKind insider stock sale carries limited weight relative to a 9% royalty now at risk for the company. Royalty risk introduces moderate revenue uncertainty but does not signal immediate strategic or operational overhaul.

MannKind Corporation shares rise 20% after FDA approval of Afrezza. FDA approval of Afrezza opens commercial pathway for MannKind's primary product driving substantial revenue growth potential.

MannKind awarded Breakthrough T1D grant to advance INHALE-1ST pediatric trial of Afrezza in youth with newly-diagnosed T1D. Grant funds pediatric trial expansion for core product Afrezza, opening new patient segment.

New clinical data for Afrezza and FUROSCIX prompts review of MannKind (MNKD) stock performance and company valuation. New Afrezza and FUROSCIX clinical data directly affects MNKD product pipeline and market valuation.

Clinical and real-world data at ADA 2026 support MannKind’s Afrezza in pediatric care, pregnancy and automated insulin delivery systems. Positive data on Afrezza expansion into pediatrics, pregnancy and AID systems can drive new adoption, regulatory progress and revenue growth.

MannKind advances clinical trials for inhaled IPF therapy. Clinical trial advancement for new inhaled IPF therapy represents major strategic R&D progress that can significantly shift MannKind's pipeline and investor outlook.